Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sovateltide, a new drug candidate, in treating patients with acute cerebral ischemic stroke. This type of stroke occurs when a blood clot blocks blood flow to the brain, causing damage to brain cells. The study builds on earlier clinical trials in India that showed promising results in improving neurological function and recovery with sovateltide, encouraging further testing in the United States and other countries. The trial compares sovateltide combined with standard care against a placebo normal saline plus standard care. Participants will receive three intravenous doses of sovateltide or placebo on days 1, 3, and 6 after stroke onset. Each dose is given as a one-minute IV bolus within 24 hours of stroke symptoms beginning. The study is randomized, double-blind, and placebo-controlled to rigorously assess the treatments impact. Participants will be monitored for 90 days after receiving treatment. Researchers will use several scales to evaluate recovery, including the modified Rankin Scale to measure disability, the National Institutes of Health Stroke Scale for neurological function, and the Barthel Index for daily living activities. Quality of life assessments and cognitive tests will also be done. Safety is closely watched for any adverse events or complications during the study period. The total participation time is about three months following treatment.
Actively Recruiting
This research aims to observe the long-term safety and effectiveness of DTX401 in people with Glycogen Storage Disease Type Ia GSDIa for at least 10 years after treatment. The study follows participants who previously received either a full or partial dose of DTX401, either in a clinical trial or after the drug was approved for use. Participants are monitored without receiving any new treatment as part of the study. They include two groups those treated with DTX401 in earlier clinical trials and those treated in post-marketing settings. The study collects information over a period of at least 10 years to track health outcomes and any side effects related to DTX401. During this time, participants undergo regular assessments including reports on serious adverse events, pregnancy outcomes, dietary intake, glucose levels, and clinical events related to GSDIa. Researchers also measure quality of life, hospital visits, and work or school attendance. The study involves ongoing data collection to understand the long-term effects and safety of DTX401, with participation lasting up to 10 years or more.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a combination of the hexavalent OX40 agonist antibody ordastobart INBRX-106 with the anti-PD-1 antibody pembrolizumab compared to pembrolizumab alone plus placebo in phase 3 as the first-line treatment for patients with recurrent or metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma HPV OPSCC that expresses PD-L1. This phase 23 seamless randomized controlled trial aims to provide new treatment insights for this patient group. Participants will receive either INBRX-106 plus pembrolizumab or pembrolizumab alone with placebo in phase 3. Both treatments are given by intravenous infusion every three weeks. The study includes two parts phase 2 focusing on objective response rates over one year, and phase 3 assessing progression-free survival and overall survival over up to four years. During the study, participants will be closely monitored through regular assessments including tumor measurements according to RECIST 1.1, clinical evaluations, and safety checks. Researchers will measure outcomes such as response rates, progression-free survival, overall survival, and the incidence of treatment-related side effects. The study also evaluates quality of life and time to chemotherapy. Participants may be followed for up to four years after starting treatment.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.